Health Affairs’ Jeff Byers sits down with Georgetown University’s Katie Keith to break down the newly proposed HHS rule that could bring major changes to the ACA beginning in 2027.

Rabih Torbay is president and CEO of Project HOPE, in Washington, D.C. A record 108 million people worldwide had been forced to leave their homes by the end of 2022 because of the climate crisis, ...

There is an alternative to the One Big Beautiful Bill’s approach of kicking millions of people off their health care and ...

How states implement new Medicaid cost-sharing rules created by the OBBBA will have significant impact on program efficiency and enrollee health.

The authors lay out prominent and pressing threats to public and planet health, though the reader needs to wait until the end to find out what can be done to save our planet and the people who live on ...

While not a comprehensive review of the pandemic, this book can provide a useful roadmap for the next serious Administration’s public health leaders who seek to get ahead of impending pandemic threats ...

Daniel R. Arnold ([email protected]), Brown University, Providence, Rhode Island. Brent D. Fulton, University of California Berkeley, Berkeley, California. During the past several decades, physicians ...

Health Affairs' Rob Lott interviews Dr. Robert Wachter, Professor and Chair of the Department of Medicine at UCSF, about his ...

The 2028 negotiation cycle marks another major inflection point in the implementation of the Medicare Drug Price Negotiation Program—its first year incorporating Part B drugs and its first opportunity ...

Older adults with dementia may be at high risk for abuse, but the topic has not been well studied. We conducted a literature review to examine the relationships between elder abuse and dementia. We ...

Precision medicine has transformed diagnosis and treatment, yet prevention often remains anchored in assumptions that no longer reflect how risk is acquired across the life-course.

Transparency Scorecard to increase visibility into non-clinical dimensions of MA plan performance that fall outside the appropriate scope of Star Ratings.